Cargando…
Radium-223 Chloride: A New Treatment Option for Metastatic Castration-Resistant Prostate Carcinoma
In the last few years, the treatment of castration-resistant prostate carcinoma (CRPC) has changed completely. The approval of docetaxel and subsequent investigation in this field have led to development of new agents that have demonstrated an improvement in overall survival in the post-docetaxel se...
Autores principales: | Pinto, Álvaro, Cruz, Patricia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3586060/ https://www.ncbi.nlm.nih.gov/pubmed/23190319 http://dx.doi.org/10.2165/11636250-000000000-00000 |
Ejemplares similares
-
Radium-223 in metastatic castration resistant prostate cancer
por: Vuong, Winston, et al.
Publicado: (2014) -
Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease
por: Harrison, Michael R, et al.
Publicado: (2013) -
Radium-223 for the treatment of castration-resistant prostate cancer
por: El-Amm, Joelle, et al.
Publicado: (2015) -
Radium-223 and metastatic castration-resistant prostate cancer: All that glitters is not gold
por: Aprile, Carlo, et al.
Publicado: (2016) -
Dutch Economic Value of Radium-223 in Metastatic Castration-Resistant Prostate Cancer
por: Peters, Michel L., et al.
Publicado: (2017)